ICICI Prudential Nifty Pharma Index Fund Regular Growth
EquityIndex FundsVery High Risk
Regular
NAV (20-Dec-24)
Returns (Since Inception)
Fund Overview
Fund Size
₹81 Cr
Expense Ratio
0.93%
ISIN
INF109KC18L6
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
15 Dec 2022
About this fund
As of 20-Dec-24, it has a Net Asset Value (NAV) of ₹17.10, Assets Under Management (AUM) of 81.27 Crores, and an expense ratio of 0.93%.
- ICICI Prudential Nifty Pharma Index Fund Regular Growth has given a CAGR return of 30.89% since inception.
- The fund's asset allocation comprises around 100.27% in equities, 0.00% in debts, and -0.27% in cash & cash equivalents.
- You can start investing in ICICI Prudential Nifty Pharma Index Fund Regular Growth with a SIP of ₹1000 or a Lumpsum investment of ₹1000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+38.52%
— (Cat Avg.)
Since Inception
+30.89%
— (Cat Avg.)
Portfolio Summaryas of 30th November 2024
| Equity | ₹81.48 Cr | 100.27% |
| Others | ₹-0.22 Cr | -0.27% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹19.88 Cr | 25.18% |
| Cipla Ltd | Equity | ₹8.5 Cr | 10.76% |
| Dr Reddy's Laboratories Ltd | Equity | ₹7.74 Cr | 9.80% |
| Divi's Laboratories Ltd | Equity | ₹7.45 Cr | 9.43% |
| Lupin Ltd | Equity | ₹5.25 Cr | 6.65% |
| Aurobindo Pharma Ltd | Equity | ₹3.89 Cr | 4.92% |
| Alkem Laboratories Ltd | Equity | ₹3.01 Cr | 3.81% |
| Torrent Pharmaceuticals Ltd | Equity | ₹2.94 Cr | 3.73% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹2.54 Cr | 3.22% |
| Mankind Pharma Ltd | Equity | ₹2.51 Cr | 3.17% |
| Zydus Lifesciences Ltd | Equity | ₹2.49 Cr | 3.16% |
| Ipca Laboratories Ltd | Equity | ₹2.15 Cr | 2.72% |
| Laurus Labs Ltd | Equity | ₹1.92 Cr | 2.44% |
| Abbott India Ltd | Equity | ₹1.5 Cr | 1.90% |
| Biocon Ltd | Equity | ₹1.42 Cr | 1.79% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹1.39 Cr | 1.76% |
| Gland Pharma Ltd | Equity | ₹1.31 Cr | 1.65% |
| Ajanta Pharma Ltd | Equity | ₹1.28 Cr | 1.63% |
| Natco Pharma Ltd | Equity | ₹1.26 Cr | 1.60% |
| Net Current Assets | Cash | ₹-1.18 Cr | 1.50% |
| Treps | Cash - Repurchase Agreement | ₹0.9 Cr | 1.14% |
| Granules India Ltd | Equity | ₹0.82 Cr | 1.04% |
Allocation By Market Cap (Equity)
Large Cap Stocks
65.35%
Mid Cap Stocks
27.76%
Small Cap Stocks
7.16%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹79.25 Cr | 100.36% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Fund Managers
Nishit Patel
Since December 2022
Priya Sridhar
Since February 2024
Additional Scheme Detailsas of 30th November 2024
ISIN INF109KC18L6 | Expense Ratio 0.93% | Exit Load No Charges | Fund Size ₹81 Cr | Age 2 years | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Pharma TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Index Funds Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹585.00 Cr | 28.9% |
| ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹585.00 Cr | 28.2% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹505.89 Cr | 24.6% |
| SBI Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹702.68 Cr | 28.3% |
| DSP Nifty 50 Equal Weight Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹1895.15 Cr | 13.5% |
| SBI Nifty Smallcap 250 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1247.77 Cr | 31.6% |
| SBI Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹702.68 Cr | 29.0% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹505.89 Cr | 25.3% |
| DSP Nifty 50 Equal Weight Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1895.15 Cr | 14.1% |
| SBI Nifty Smallcap 250 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹1247.77 Cr | 30.8% |
About the AMC
ICICI Prudential Mutual Fund
Total AUM
₹8,87,010 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Other Funds by ICICI Prudential Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of ICICI Prudential Nifty Pharma Index Fund Regular Growth?
What is the portfolio composition of ICICI Prudential Nifty Pharma Index Fund Regular Growth?
Who manages the ICICI Prudential Nifty Pharma Index Fund Regular Growth?
- Nishit Patel
- Priya Sridhar
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.